MDA-MB-468 Cells

The MDA-MB-468 cell line is a well-established human breast cancer cell line derived from the pleural effusion of an adult patient with metastatic adenocarcinoma. These cells are characterized by their epithelial morphology and are known for their high degree of aneuploidy. MDA-MB-468 cells are estrogen receptor-negative (ER-) and are often used as a model to study triple-negative breast cancer (TNBC), a subtype of breast cancer that lacks estrogen receptor (ER), progesterone receptor (PR), and HER2/neu expression. This makes MDA-MB-468 a critical tool for research into cancers that do not respond to hormonal therapy or HER2-targeted treatments.

Genetically, MDA-MB-468 cells exhibit mutations in the TP53 gene, which is a common occurrence in various forms of cancer and plays a significant role in cell cycle regulation and apoptosis. The cell line also shows amplification of the epidermal growth factor receptor (EGFR) gene, contributing to its utility in studying the EGFR signaling pathway and its implications in cancer progression and treatment resistance. Researchers frequently utilize MDA-MB-468 cells to investigate mechanisms of drug resistance, test new therapeutic agents, and explore the molecular biology of aggressive breast cancers.

In addition to their genetic and phenotypic characteristics, MDA-MB-468 cells are known for their ability to form xenografts in immunocompromised mice, making them a valuable model for in vivo studies of tumor growth and metastasis. This cell line’s responsiveness to various chemotherapeutic agents and targeted therapies is extensively studied to develop effective treatment strategies for TNBC. Overall, the MDA-MB-468 cell line is a crucial resource for advancing breast cancer research, particularly in the context of triple-negative and EGFR-positive malignancies.